Immuno-Oncology Drives Better Outcomes In NSCLC, But Is This Now An Overcrowded Space?

Barely a month passes without an announcement of improved survival rates for non-small cell lung cancer (NSCLC) patients. Much of this has been driven by favouring a personalised medicine approach over the historic “one size fits all” chemotherapy paradigm. Drugs which target specific mutations such as EGFR and ALK have been at the forefront and this has been further supplemented with the application of anti-PD-1/PD-L1 agents (as monotherapies or in combination) where Merck’s Keytruda® (Pembrolizumab) has been leading the charge. In fact, ASCO 2018 has solidified Merck’s dominant position in first line settings.

Immuno-Oncology Drives Better Outcomes In NSCLC, But Is This Now An Overcrowded Space?

Download Request

China Healthcare 2.0 – Age of Consolidation, Innovation and Capital Deployment

Despite the impressive growth observed in China over the last two decades and with a projected healthcare market of RMB 8 trillion (USD 1.2 trillion), Chinese life science companies lag behind toptiered Western counterparts, both in terms of market capitalisation and innovation. What makes 2017 remarkable is that the age of pure window shopping by Chinese players seems to be something of the past and companies are actively pursuing international strategies. Ambitious and visionary pharmaceutical companies and healthcare investors are all establishing their footprints across the world. The next five years point to exponential growth in crossborder knowledge and capital exchange, offering unprecedented opportunities for deal making between the West and the East for those who are prepared. This article highlights some of the changes, opportunities and challenges. We believe that three key themes will dominate this coming period: industry consolidation, technological innovation and optimisation of capital operation and deployment.

China Healthcare 2.0 - Age of Consolidation, Innovation and Capital Deployment

Download Request

EU medical device and diagnostic regulatory overhaul: Key changes and their impact

On May 26th 2017, a new set of European Medical Device Regulations (“MDR”) and In Vitro Diagnostic Regulations (“IVDR”) entered into force. They represent a major overhaul and tightening of the previous directives and affect all companies marketing or developing devices and/or diagnostics under their name or trademark in the EU (termed ‘manufacturers’ in the regulations). The changes introduce a standardised regulatory framework for the EU that aims to be robust, transparent, and to overcome differences in interpretation and weaknesses brought to light in recent safety scandals.

EU medical device and diagnostic regulatory overhaul: Key changes and their impact

Download Request

Pharma is attracted to antibody deals in Oncology

Today the top ten best-selling antibody therapeutics for cancer have accumulated revenues approaching $200 Billion, the bulk of which is accounted for by sales of the four leading agents.

Pharma is attracted to antibody deals in Oncology

Download Request

The Upsurgence of Nanotechnology

The term Nanotechnology refers to the domain of science and engineering that is applied to structures and materials that measure only a few billionths of a meter.  The term was coined by Japanese scientist Norio Taniguchi almost 40 years ago, and then popularised by Eric Drexler in his “Engines of Creation: The Coming Era of Nanotechnology” in 1986.  Over the next 20 years the convergence of experimental advances in manipulation of materials no bigger than the width of a DNA molecule facilitated the development of this field from the closed confines of leading research labs into the world of applications for the general public.  At the beginning of this century President Clinton put a political seal of approval on the sector by announcing the U.S. National Nanotechnology Initiative (NNI). 


It is hard to believe the technology is almost 40 years old as it is only in the last 5-10 years that Nanotechnology has found favour in commercially viable products.  Among areas where it is having the most significant impact is medicine.

The Upsurgence of Nanotechnology

Download Request

Reducing Pain for Patients and Dealmakers

Pain management continues to face the dual hurdles of abuse of the most efficacious (opiod based) therapies and the difficulties of developing and commercialising new treatments. This challenging environment presents difficulties both for large pharmaceutical companies looking to bring new solutions to market and the mid size and smaller biotechs developing new approaches and seeking commercial partners. 

Reducing Pain for Patients and Dealmakers

Download Request